ClinicalTrials.gg
RecruitingNCT07623850JLM019Updated Jun 3, 2026

A Phase I Study of JLM019 Injection

A Phase 1 interventional study of JLM019 Injection in Advanced Solid Tumor (Phase 1), Hodgkin Lymphoma and Non-Hodgkin Lymphoma, sponsored by Jecho Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Jecho Biopharmaceuticals Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jan 2026, registered May 2026).
  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
115
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 57 studies in Hodgkin Disease with a site in China — 28 open to participants now, 31 under way, 3 of them phase 3. Hodgkin Disease · China.

Planned enrollment
11th of 53
115 · median 75
Started
2026
with 2 others
Phase 1
8 of 57
4 open now
Primary completion
2029-03
later than 27 of 30 live
Registered
54th of 57
by date

Among the 57 studies in Hodgkin Disease with a site in China, this one is the 11th largest by planned enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2026, is one of 8 in phase 1, reaches primary completion later than 27 of the 30 other live ones, and was the 54th registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 161 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

28 of the 57 studies in Hodgkin Disease with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 134 Hodgkin Disease studies recruiting now, 71 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Hodgkin Disease with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, single-arm, open-label, dose escalation phase (Part A) and dose expansion (Part B) study to evaluate the safety and tolerability of JLM019 Injection in patients with advanced malignancies.

The study subjects are adults with advanced malignancies including advanced solid tumors or relapsed/refractory lymphoma.

During the dose escalation phase, the dose escalation scheme is the accelerated titration in 0.001 - 0.2 mg/kg cohorts plus a traditional '3 + 3' design in 0.6 - 10 mg/kg cohorts, jointly in nine dose cohorts 0.001, 0.01, 0.05, 0.2, 0.6, 1.5, 3, 6 and 10 mg/kg. JLM019 Injection is intended to be administered once a week (QW). However, the dose and interval of administration may be adjusted based on the acquired PK, PD, and safety data. Each treatment cycle is 28 days.The repeated dose is tentatively scheduled to be administered once weekly until one of the following occurs: disease progression, intolerable toxicity, requirement for new antitumor therapy, withdrawal of informed consent form, death, loss to follow-up, or other protocol-specified discontinuation conditions.

Safety profile, DLT, MTD and RED of JLM019 Injection shall be assessed during and after treatment, with PK, PD, immunogenicity and Efficacy analyzed correspondingly.

Read the detailed description

1. Dose Escalation Rules

  1. If one Grade ≥ 2 treatment-emergent adverse event (TEAE) during the DLT observation period after the first dose at any dose level in Part A Dose Escalation will Add one more enrolled participant. If the supplementary enrolled subject also experiences ≥Grade 2 treatment-emergent adverse event will trigger the transition from accelerated titration to the traditional '3 + 3' cohort design.
  2. At the '3 + 3' dose escalation stage, a sentinel cohort will be employed. If no DLTs occur in the sentinel cohort within 14 days after the drug administration, the other two patients will be enrolled at once in this dose group. If DLTs occur in the sentinel cohort, the other two patients will also be enrolled sequentially.
  3. At the '3 + 3' dose escalation stage,

    1. If the first 3 patients at this dose level experience no DLTs during the observation period, the dose will be escalated.
    2. If 1 of the first 3 patients experienced DLTs or 2 of the first 3 patients of a cohort have Grade ≥ 2 CRS or neurotoxicity, another 3 patients will be enrolled in this group again, and dose escalation will be evaluated based on these 6 patients:
    3. If 1 of 6 patients experience DLTs, the dose will be escalated.
    4. If ≥ 2 of 6 patients experience DLTs, the dose escalation will be stopped.
    5. If ≥ 2 of the first 3 patients experienced DLTs, the dose escalation will be stopped.
  4. If MTD is reached at the starting dose level, a lower dose level will be considered.
  5. Upon completion of DLT observation for each dose level, SRC will determine whether to terminate dose escalation or continue for further escalation or expand the dose groups based on a comprehensive review of the collected data.
  6. The Recommended Expansion Dose (RED) will be determined based on the assessments of safety, efficacy, and PK data, regardless of whether the MTD is achieved.

2. Statistical Analysis 2.1 Safety Analysis AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). AEs will be graded according to NCI CTCAE v6.0. AEs will be summarized by treatment group, System Organ Class (SOC), and Preferred Term (PT). Summaries will include (but not limited to): number of cases and incidence rates for all AEs, drug-related AEs, serious AEs (SAEs), drug-related SAEs, AEs leading to treatment discontinuation, and fatal AEs. For clinical safety assessments (laboratory tests, vital signs, physical examinations, 12-lead ECGs, etc.), treatment related changes from baseline will be described. Treatment-emergent abnormal findings will be listed in tables. During the dose-escalation phase, the incidence of DLTs will be calculated for each dose cohort.

2.2 PK Analysis Drug concentration data in peripheral blood will be analyzed by dose cohort according to scheduled PK sampling time-points. Individual and mean concentration-time profiles will be plotted for each dose cohort using both linear and semi-logarithmic scales. For summary statistics (e.g., mean concentration) and mean profile plots: Scheduled PK sampling time will be used. For individual patient concentration-time curves: Actual PK sampling time will be used.

PK parameters including: Cmax, Tmax, t1/2, AUC0\~inf, AUC0\~t, CL/F, and Vz/F, will be analyzed by using non-compartmental analysis (NCA) for each dose cohort. Descriptive statistics will include number of subjects (n), arithmetic mean, standard deviation (SD), coefficient of variation (CV%), minimum, and maximum. For key parameters (e.g., Cmax and AUC0-inf), geometric mean and geometric CV% will also be reported.

2.3 PD Analysis Descriptive statistical methods will be used to analyze PD parameters by treatment groups. Time-course profiles of PD markers will be plotted.

2.4 ADA Analysis Descriptive summaries will be provided for the time and the proportion of ADA-positive subjects following investigational drug administration. ADA positive subjects will undergo Nab testing, and the time and incidence of Nab occurrence will be summarized.

2.5 Efficacy Analysis ORR and DCR will be reported as the number and percentage of subjects in each dose cohort, with 95 % confidence intervals (CIs) estimated by using the Clopper-Pearson method. For time-to-event endpoints (PFS, DOR, OS), median survival duration and corresponding 95 % CIs will be estimated for each dose cohort by using the Kaplan-Meier method. Kaplan-Meier survival curves will be plotted for the event occurrence over the time.

03

Conditions studied

  • Advanced Solid Tumor (Phase 1)
  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Eighteen years of age or older;
  2. Patients with histopathologically or confirmed advanced solid tumors () or (r/r) Hodgkin's/Non-Hodgkin's lymphomas (HL/NHL, including transformed lymphomas):

    • AST subtypes include but are not limited: colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), gastric cancer (GC), ovarian cancer (OV), renal cell carcinoma (RCC), melanoma, biliary tract cancer (BTC), alveolar soft part sarcoma (ASPS), etc.
    • HL/NHL subtypes include but are not limited: classical Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL), mantle cell lymphoma (MCL), etc.
  3. as defined as:

    • AST: At least one tumor lesion ≥ 10 mm in the longest diameter as assessed by computed tomography (CT);
    • HL/NHL: Fluorodeoxyglucose (FDG) avid disease by positron emission tomography (PET) and ≥ 1 lesion > 15 mm in the longest diameter by > 10 mm in the short axis, as assessed by CT;
  4. Patients with the following molecular profiles will be prioritized for enrollment:

    • High tumor T-cell infiltration (e.g., elevated T-cell GEP score);
    • TMB > 10 mut/Mb、MSI-H/dMMR status or POLE/POLD1 mutations. Absence of β2M and JAK1/JAK2 loss-of-function mutations.
  5. Submission of tumor representative of the current disease, which may consist of any of the following:

    • Archived formalin-fixed paraffin-embedded (FFPE) tissue block;
    • At least 15-20 slides of tumor tissue from an FFPE block suitable for immunohistochemistry (IHC), including ≥ 10 % tumor content per section with ≥ 20 mm2 of evaluable tissue which may include ≤ 50 % tumor adjacent tissue;
    • A fresh tumor biopsy obtained by surgical excision or core needle procedure prior to the first dose of JLM019 Injection;
  6. For patients with accessible tumors, willingness to undergo on-study biopsy as scheduled in the protocol;
  7. (ECOG) performance status grade 0\~1;
  8. ≥ 3 months estimated by the Investigator;
  9. Recovery to Grade ≤ 1 for any non-laboratory toxicity resulting from previous anticancer therapy prior to the first dose of product (except alopecia, hearing loss, Grade ≤ 2 neuropathy, or endocrinopathy managed with replacement therapy);
  10. Adequate baseline hematologic, renal, hepatic, and cardiac function as defined by:

    • Lymphocyte ≥ 0.5 × 109/L;
    • ≥ 1.5 × 109/L;
    • count (PLT) ≥ 100 × 109/L;
    • (HGB)≥ 90 g/L (no packed red blood cell transfusion within the prior 2 weeks);
    • Serum total (TBIL) ≤ 1.5 × (ULN) or ≤ 3 × ULN for patients with Gilbert's disease;
    • Estimated (eGFR) ≥ 30 mL/min/1.73 m2, as calculated by the Modification of Diet in Renal Disease (MDRD) formula;
    • ALT and AST ≤ 2.5 × ULN (≤ 5 × ULN if there is evidence of hepatic involvement by malignant disease);
    • (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN unless the patient is receiving anticoagulant therapy in which PT or aPTT is within therapeutic range of intended use of anticoagulants;
    • High sensitivity cardiac troponin I (hs-cTnI) and N-terminal pro B-type natriuretic peptide (NT-proBNP) ≤ ULN (asymptomatic abnormalities may be permitted after clearance by cardiology consultation).
  11. All patients and their partners must have no plans for conception from screening period and during the trial, and agree to practice effective during the trial and for 4 months after the last dose of JLM019.
  12. Able to participate and willing to give written form.

Exclusion criteria

Exclusion Criteria:

  1. Allergy to JLM019 Injection components;
  2. History of Grade 4 infusion-related, anaphylactic or allergic reaction to any previous monoclonal antibody or other Fc-based protein therapy;
  3. Experienced any cardiovascular immune-related adverse event (irAE), or discontinued from that treatment due to a Grade 3 or higher irAE in previous ICI therapy;
  4. Any serious or uncontrolled health conditions listed below:

    • Patients with concurrent infections requiring intravenous antimicrobial therapy within the past 2 weeks, or with unexplained fever (body temperature ≥ 37.5 °C);
    • History of vascular diseases within the past 6 months (including myocardial infarction, unstable angina, cerebrovascular diseases, and peripheral arterial or aortic diseases);
    • Uncontrolled hypertension (defined as systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg on at least two separate occasions after antihypertensive treatment);
    • Individuals with active thrombosis, active bleeding, or pathological conditions associated with high bleeding risk (such as coagulation disorders);
    • Has an active disease that has required systemic treatment (i.e., with use of disease modifying agents, , or drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment;
    • Any serious or uncontrolled cardiovascular condition, including but not necessarily limited to:

      1. Any history of myocarditis of any etiology;
      2. History of Class III or IV congestive heart failure, myocardial infarction, unstable angina, cerebrovascular accident, cardiac hospitalization, or other acute uncontrolled heart disease within 6 months of scheduled C1D1;
      3. \< 45 % on screening echocardiogram;
      4. Any findings on screening such as atrial or ventricular arrythmia (other than sinus tachycardia) or AV conduction abnormality such as left bundle branch block (such patients may be enrolled after cardiology clearance and Sponsor approval);
  5. History of (non-infectious) pneumonitis / interstitial lung disease or current pneumonitis / interstitial lung disease;
  6. Presence of any active central nervous system (CNS; brain or ) . Solid tumor patients with are eligible if previously treated and there is no magnetic resonance imaging (MRI) evidence of progression for ≥ 8 weeks after treatment is complete and within 28 days prior to first dose of JLM019 Injection;
  7. Prior organ allograft or hematopoietic stem cell transplantation (HSCT). Lymphoma patients ≥ 3 months post-HSCT with no evidence of active may be eligible upon approval by the Investigator or Sponsor;
  8. Receipt of any of the following within the timeframes indicated, before first scheduled dose of JLM019 Injection:

    1. , including PD-(L)1 (e.g., pembrolizumab, nivolumab, cemiplimab, avelumab, durvalumab), CTLA-4 (e.g., ipilimumab, tremelimumab) and Lag-3 (e.g., relatlimab), or costimulatory agonists (including but not limited to CD28, CD134 (OX40), CD137 (4-1BB)): 3 months (135 days for atezolizumab);
    2. Chemotherapy, small molecule anticancer agents (e.g., kinase inhibitors), or radiation: 2 weeks. Note: for lung cancers or mesotheliomas, radiation therapy to the lung that is > 30 Gy within 6 months;
    3. Other monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, antibody-like drugs, cytokines, cell therapies, or radio immunoconjugates: 4 weeks (2 weeks permissible with documented disease progression and approval by the medical monitor or Sponsor);
  9. Currently participating in another clinical trial or has participated in another clinical trial within 4 weeks prior to the first dose of the study treatment. Note: Patients who have entered the follow-up phase of another study may be enrolled if at least 4 weeks have elapsed since their last dose of study treatment;
  10. Any condition requiring systemic treatment with either corticosteroids (> 10 mg/day prednisone or equivalent) or other immunosuppressive medications within 14 days of the first dose of JLM019 Injection. Inhaled, intranasal or topical corticosteroids or adrenal replacement doses of corticosteroids are permitted in the absence of active autoimmune disease;
  11. Received a live or within 30 days prior to the first dose of JLM019 Injection. Note: Administration of inactivated vaccines is allowed;
  12. Received radiotherapy within 2 weeks of start of study treatment or had a history of radiation pneumonitis. Note: Patients must have recovered from all radiation-related toxicities, not required corticosteroids, and show no evidence of radiation pneumonitis. A 1-week is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-CNS disease;
  13. Any second active within the previous 3 years( (except adequately treated carcinoma in situ of cervix, basal cell carcinoma or squamous cell skin carcinoma));
  14. Patients with a history of AIDS, syphilis, or active hepatitis [For : positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and HBV-DNA copy number above the upper limit of quantification; for : positive HCV antibody and HCV RNA copy number above the upper limit of quantification].
  15. Pregnancy or lactation, and a woman of (WOCBP) who has a positive pregnancy test (within 7 days) prior to treatment;
  16. Patients deemed unsuitable for participation in this study at the Investigator's discretion.
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
115 participants (estimated)

Study arms

  • Experimental
    JLM019 Injection

    The JLM019 Injection will be administered via intravenous (IV) infusion at dose levels of 0.001, 0.01, 0.05, 0.2, 0.6, 1.5, 3, 6, and 10 mg/kg. Each IV infusion must last at least 30 min. The repeated dose is tentatively scheduled to be administered once weekly until one of the following occurs: disease progression, intolerable toxicity, requirement for new antitumor therapy, withdrawal of informed consent form, death, loss to follow-up, or other protocol-specified discontinuation conditions. (Note: The dose and administration interval may be adjusted based on acquired PK, PD and safety data).

    Biological: JLM019 Injection

Interventions

  • BiologicalJLM019 Injection

    The JLM019 Injection will be administered via intravenous (IV) infusion at dose levels of 0.001, 0.01, 0.05, 0.2, 0.6, 1.5, 3, 6, and 10 mg/kg. Each IV infusion must last at least 30 min. The repeated dose is tentatively scheduled to be administered once weekly until one of the following occurs: disease progression, intolerable toxicity, requirement for new antitumor therapy, withdrawal of informed consent form, death, loss to follow-up, or other protocol-specified discontinuation conditions. (Note: The dose and administration interval may be adjusted based on acquired PK, PD and safety data).

06

What researchers measure

Primary outcomes

  1. Number of participants with reported Dose-limiting toxicity (DLT)

    Evaluate according to the DLT standards specified in the protocol

    Time frame: Within 28 days after the first dose

  2. Rate of adverse events

    In accordance with NCI CTCAE v5.0, the toxicity assessment will be conducted

    Time frame: Up to 3 years

  3. Determine the recommended dose for combination for JLM019 injection

    Evaluate the data from the Phase Ia study to determine recommended dose for combination for JLM019 injection in Phase Ib

    Time frame: Up to 3 years

Secondary outcomes

  1. Determination of JLM019 concentrations

    Assays were performed by ELISA at the central laboratory

    Time frame: Up to 12 months

  2. Detection of anti-JLM019 antibodies in serum

    Assays were performed by ELISA at the central laboratory

    Time frame: Up to 12 months

  3. Determination of detailed blood lymphocyte subsets

    Assays were performed by flow cytometry at the central laboratory

    Time frame: Up to 12 months

  4. Determination of cytokines in blood

    Assays were performed by ELISA at the central laboratory

    Time frame: Up to 12 months

  5. Objective response rate

    Assessed according to RECIST 1.1 based on radiological examinations (CT/MRI/ultrasound)

    Time frame: Up to 12 months

  6. Disease control rate

    Assessed according to RECIST 1.1 based on radiological examinations (CT/MRI/ultrasound)

    Time frame: Up to 12 months

  7. Progression-free survival

    Evaluated via regular follow-up; Disease progression is determined per RECIST 1.1

    Time frame: Up to 15 years

  8. Duration of response

    Evaluated via regular follow-up ; Disease progression is determined per RECIST 1.1

    Time frame: Up to 15 years

  9. Overall survival

    Evaluated via regular follow-up ; Disease progression is determined per RECIST 1.1

    Time frame: Up to 15 years

07

Study locations

1 of 1 sites recruiting
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100730, China
    Recruiting
    • Ba yi, Doctor of Medicine · Contactbayi@tjmuch.com · 86+010-69158373
    • Han xiaohong, Doctor of Medicine · Contact86+010- 69154796
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2029, 38 months after the start.

Of 91 phase 1 interventional studies under Hodgkin Disease, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 79. This study's planned 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
Jun 3, 2026
StartActual
Jan 13, 2026
Primary completionEst.
Mar 14, 2029
CompletionEst.
Jul 1, 2029
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07623850
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Jan 13, 2026
Primary completion
Mar 14, 2029 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Jun 3, 2026

Study contacts

hailong zhang
Contact
hailong.zhang@jechobio.com
+8613332000582

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion